# Trust & Completeness — Primary Runtime Batch 4 and Completion

Date: 2026-07-15

## Batch outcome

- Compounds reviewed and updated: 19
- Structured workbook entries revised: 38
  - `runtime_safety`: 19
  - `contraindications_or_flags`: 19
- New evidence-limited contraindication exceptions documented: 8
- Trust audit: 70/89 complete before; 89/89 complete after
- Trust validation errors: 0
- Strict full-public actionable safety gaps: 0

## Compounds completed

`coq10`, `creatine`, `creatine-beta-alanine`, `creatine-hcl`, `creatine-monohydrate`, `curcumin-piperine`, `egcg-caffeine`, `l-theanine-sleep`, `magnesium-citrate`, `magnesium-oxide`, `magnesium-threonate`, `melatonin`, `melatonin-extended-release`, `omega-3`, `protein-whey-isolate`, `psyllium-husk`, `vitamin-d`, `vitamin-d3`, and `vitamin-d3-k2`.

## Key evidence decisions

- Removed categorical renal and hydration/nephrotoxic-stacking claims from creatine profiles; current reviews distinguish a serum-creatinine change from demonstrated filtration decline and have limited evidence in pre-existing kidney disease.
- Kept creatine monohydrate evidence separate from creatine HCl and an unspecified creatine–beta-alanine combination.
- Replaced pipeline/editorial instructions in melatonin and L-theanine sleep runtime fields with reader-facing safety evidence.
- Added formulation-specific liver guidance for curcumin–piperine and concentrated EGCG–caffeine rather than generalizing from foods or unrelated forms.
- Added supported renal-clearance and oral-absorption precautions to the remaining magnesium forms.
- Replaced severity tokens with specific milk-protein allergy, psyllium obstruction, vitamin D excess, and vitamin K antagonist flags where evidence supported them.

## Evidence limitations

Eight exact compounds or formulations lack reliable evidence for a categorical contraindication. Their fields remain intentionally empty and are documented in `data-sources/safety-evidence-limited-primary-runtime-exceptions.json`. Unsupported fields were not filled for completion's sake.

## Overall completion report

- Total unique compounds reviewed across the expanded safety/trust queue: 89
- Total compounds with safety or trust metadata updated: 89
- Workbook structured-safety field revisions across all four safety/trust phases: 225
- Evidence-labelled `runtime_safety` entries added or replaced: 89
- Documented evidence-limited contraindication exceptions: 59 (41 full-public and 18 primary-runtime)
- Strict safety audit: 0 remaining actionable full-public gaps
- Expanded trust audit: 89/89 complete, 0 remaining, 0 errors
- Audit improvement: trust coverage increased from 0/89 to 89/89; strict safety coverage remains at zero actionable gaps after the completed safety pass

## Validation

- Workbook patch dry-run and human-reviewed apply: pass
- Workbook schema and source-of-truth guard: pass
- Core data build and workbook/runtime parity: pass
- Trust audit: pass, 89/89, 0 errors
- Strict contraindication audit: pass, 0 actionable gaps
- TypeScript: pass
- ESLint: pass with zero warnings
- Vitest: pass (97 files, 606 tests)
- Production static export: pass (20 deploy steps, 1,187 pages)

## Recommended next priorities

1. Extend the same evidence-labelled trust contract to `cluster_member_runtime` profiles.
2. Review `hidden_until_grounded` profiles only when promotion is planned; do not bulk-fill unsupported fields.
3. Add a schema-supported medication-interaction field in a separately scoped architecture proposal if structured interaction extraction is required. The current 52-column schema has no standalone interaction column, so this pass preserved schema and placed supported interaction guidance in existing safety fields.
